Cargando…
Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
We have previously described the generation of a novel Ebola virus (EBOV) vaccine platform based on (a) replication-competent rabies virus (RABV), (b) replication-deficient RABV, or (c) chemically inactivated RABV expressing EBOV glycoprotein (GP). Mouse studies demonstrated safety, immunogenicity,...
Autores principales: | Blaney, Joseph E., Marzi, Andrea, Willet, Mallory, Papaneri, Amy B., Wirblich, Christoph, Feldmann, Friederike, Holbrook, Michael, Jahrling, Peter, Feldmann, Heinz, Schnell, Matthias J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667758/ https://www.ncbi.nlm.nih.gov/pubmed/23737747 http://dx.doi.org/10.1371/journal.ppat.1003389 |
Ejemplares similares
-
Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection
por: Marzi, Andrea, et al.
Publicado: (2016) -
A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
por: Domi, Arban, et al.
Publicado: (2018) -
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
por: Geisbert, Thomas W., et al.
Publicado: (2002) -
Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever
por: Marzi, Andrea, et al.
Publicado: (2012) -
Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates
por: Geisbert, Thomas W., et al.
Publicado: (2008)